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Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer 
death in both men and women. Due to the difficulty of diagnosing this 
malignancy until it has progressed to an advanced stage, treatment is often 
difficult, expensive and ineffective. The first line treatment for PDAC is 
Gemcitabine chemotherapy. However, due to its extensive side effect profile 
and the early chemo-resistance the PDAC cells develop against Gemcitabine, the 
need for alternative therapeutic methods to manage treatment is necessary. 
Therefore, this review analyzes if in individuals with advanced pancreatic ductal 
adenocarcinoma [P], does the addition of curcumin with the standard 
Gemcitabine chemotherapy [I] provide reduction in disease progression without 
causing additional adverse reactions [O] when compared to sole Gemcitabine 
chemotherapy [C]?
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Pancreatic Ductal Adenocarcinoma (PDAC) 
Overview 
o 4th leading cause of cancer related death in the world 
o 5-year survival ~8.5% 
o In 2018 alone, there was ~55,440 new cases with ~44,330 deaths 
Symptoms: 
o upper abdominal pain radiating to the back, nausea, vomiting, unintended 
weight loss, inability to digest fatty foods, or jaundice
Treatment: 
o First line treatment is Gemcitabine Chemotherapy
o Surgical resection only if diagnosis at early stage
o even after potentially curative resection, disease relapse occurs in 80% of 
individuals
Curcumin 
o derived from turmeric
o demonstrated to have antioxidant, anti-inflammatory and anticancer properties 
against various types of cancers. 
o minimal toxicity and its safety is FDA approved
Introduction
Methods
Literature Search Performed in October 2018
o PubMed, Google Scholar, and Cochrane Library 
o Search Terms: “pancreatic cancer AND curcumin” or “pancreatic 
cancer AND curcumin AND Gemcitabine”
Articles where selected based on relevance to the research 
question, publication date, results, and studies based on human 
subjects. 
Studies found some degree of efficacy in the use of 
curcumin in the treatment of PDAC compared to sole 
Gemcitabine chemotherapy.  
Strengths: 
o similar inclusion criteria  
o consistent data analysis 
o similar length of data collection 
o 5/6 studies evaluated the addition of curcumin to 
Gemcitabine during the study period 
Limitations: 
o small sample sizes
o lack of double-blind studies
o Varied study designs  
o different formulations of curcumin utilized  
Discussion Results 
Efficacy of Curcumin in the Treatment of Advanced Pancreatic Ductal 
Adenocarcinoma Compared to Sole Gemcitabine Chemotherapy 
The study results are positive, however, more research is needed in 
order to make a definitive conclusion. For patients suffering from 
advanced pancreatic ductal adenocarcinoma, curcumin appears to be 
a reasonable and potentially efficacious addition to the standard 
first-line chemotherapy, Gemcitabine, regardless of disease state. 
Curcumin has shown to provide disease stabilization. Some major 
drawbacks to this therapy is it’s lack bioavailability and the curcumin 
related toxicity experienced by participants. 
Evidence is insufficient to change current practice, but there is 
enough positive results to support and encourage future research. 
Further studies with a more bioavailable curcumin formula that 
increases serum curcumin levels in a dose depended way should be 
investigated and performed. This could potentially provide better tumor 
response and quality of life, and improved overall survival rate. 
Conclusion
There is hopeful evidence that curcumin may be efficacious in disease 
management in patients with advanced pancreatic adenocarcinoma. 
All studies demonstrated an improvement in overall survival time 
with curcumin administration when compared to the survival time with 
sole Gemcitabine chemotherapy. There was only two studies in 
which no participant saw a partial or complete tumor response, 
however stable disease status was achieved (Kanai et al, 2011 and 
Kanai et al, 2013). 
Bioavailability of curcumin was measured in 3 out of the 5 studies, but 
only one study was able to achieve dose dependent levels of 
curcumin (Kanai et al, 2013). This study used curcumin in a more 
bioavailable formulation compared to other studies.
Of the 2 studies that evaluated quality of life, only one saw 
statistically significant improvement in fatigue and functioning-
associated quality of life scores (Kanai et al, 2013). Other studies 
did show reduced side effects with curcumin use when compared to 
sole Gemcitabine therapy.  However, 3 studies had at least 1 
participant drop out due to curcumin related toxicity. 
Overall, tumor marker levels or serum proinflammatory cytokine levels 
had no correlation to tumor response. 
Study
Disease State 
at Baseline 
Overall 
Survival 
Time 
Tumor Response
Systemic 
Curcumin 
amounts 
(Bioavailability)
Toxicity due to 
Curcumin 
Administration
Dhillon et al
(2008)
Varied S S NS NS
Epellbaum et al
(2010)
Previously 
untreated 
advanced or 
metastatic 
disease 
S S n/a S
Kanai et al
(2011)
Resistant S NS NS NS
Kanai et al
(2013)
Resistant S NS S S
Pastorelli et al 
(2018)
Varied S S n/a S
Table 1. Comparison Table
Key: S= significant.    NS= not significant    n/a= not applicable 
